Bausch Health Companies vs Regeneron Pharmaceuticals
BHC and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and REGN compare
Regeneron Pharmaceuticals is the larger company, worth 32 times as much as Bausch Health Companies ($98.8B against $3.1B).
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 10.8% for Bausch Health Companies).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with −7.6% at Bausch Health Companies.
Regeneron Pharmaceuticals pays a dividend yielding 0.39%; Bausch Health Companies does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 8 for Bausch Health Companies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | REGN |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $98.8B |
| Share price | $8.35 | $955.47 |
| Change, 1 year | 20.3% | 40.2% |
| Change, 5 years | −67.9% | 46.4% |
| Beta (5Y) | 1.00 | 0.62 |
| Employees | 20K | 15K |
| StockData Score | ||
| Total score | 8 | 16 (better) |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 21.1× |
| P/S | 0.3× (better) | 5.8× |
| P/B | – | 3.0× |
| EV/EBITDA | 9.3× (better) | 17.0× |
| P/FCF | 1.7× (better) | 25.8× |
| PEG | – | 7.63 |
| FCF yield | 59.7% (better) | 3.9% |
| Fair value | $37.02 | $888.57 |
| Margin of safety | 77.4% (better) | −7.5% |
| Growth | ||
| Revenue growth (TTM) | 10.8% | 18.6% (better) |
| Revenue growth, 5Y average | 5.0% | 11.0% (better) |
| Net income growth (TTM) | −332% | 5.2% (better) |
| EPS growth (TTM) | −336% | 8.4% (better) |
| EPS growth, 5Y average | – | 6.3% |
| Profitability | ||
| Operating margin | 11.2% | 28.8% (better) |
| Net margin | −7.6% | 28.5% (better) |
| FCF margin | 16.8% | 22.6% (better) |
| Return on equity | – | 14.9% |
| Return on invested capital | 5.5% | 16.3% (better) |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Net debt / EBITDA | 7.57 (better) | −1.36 |
| Interest coverage | 0.8× | 104× (better) |
| Current ratio | 1.56 | 3.35 (better) |
| Altman Z-score | 0.22 | 7.82 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.39% |
| Payout ratio | – | 8.0% |
| Buyback yield | – | 2.0% |
| Shareholder yield | 0.00% | 2.4% (better) |
| Ownership | ||
| Held by institutions | 63.4% | 88.5% |
| Held by insiders | 31.5% | 3.7% |
| Insider net buying, 12 months | −$507K (better) | −$57.4M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 2.9% | 2.2% |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.